At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 64 enrolled
Drug / intervention
LY2523355 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of LY2523355 in Patients With Extensive-Stage Small-Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating LY2523355 and Granulocyte colony-stimulating factor (G-CSF) for Small Cell Lung Cancer. Completed, enrolled 64 participants across 11 sites in 3 countries.
Detailed Summary
Part A: This study evaluates an experimental treatment in participants with extensive-disease in small-cell lung cancer. Part B: This study evaluates an experimental treatment in participants with extensive-disease in small-cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Lung Cancer
CountriesRomania, South Korea, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2009
First PostedDec 2009
Primary CompletionJul 2012
TodayJul 2026
First PostedDec 3, 2009
Enrollment StartDec 1, 2009
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 16.6 years ago
Interventions
LY2523355drug
Administered intravenously as a 1-hour infusion
Granulocyte colony-stimulating factor (G-CSF)drug
Administered subcutaneously